

## pCODR Informational Webinar for Patient Advocacy Groups

September 15, 2011

Hello,

The pan-Canadian Oncology Drug Review (pCODR) is a newly established evidence-based cancer drug review process, designed to bring consistency and clarity to the assessment of cancer drugs by looking at clinical evidence, cost-effectiveness and patient perspectives. The information that results from this process will be used to provide recommendations to provinces and territories to guide their drug funding decisions.

Last week we held an information session for patient advocacy groups in Toronto. For those who were unable to attend, we are now inviting patient advocacy groups to participate in an informational webinar on **October 14, 2011 from 3:00 p.m. to 4:30 p.m. (EDT)**.

The objectives of the informational webinar are to:

- provide an overview of the pCODR process
- to explain how patient advocacy groups can provide input on a drug submission to pCODR

We will not be discussing any particular drug nor are we in a position to offer advice on drug access. Your provincial cancer care program should be able to answer questions of this nature.

We hope you will be able to join us at this information session. The contributions of patient advocacy groups have been invaluable in shaping the pCODR process. Please confirm your attendance at the information session via e-mail: [rsvp@pcodr.ca](mailto:rsvp@pcodr.ca) by October 7, 2011.